Organoid morphology-guided classification for oral cancer reveals prognosis

Cell Reports Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 102129 - 102129

Published: May 1, 2025

Language: Английский

---

Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies

Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216816 - 216816

Published: March 16, 2024

Pulmonary large-cell neuroendocrine carcinoma (LCNEC), a disease with poor prognosis, is classified as pulmonary high-grade carcinoma, along small-cell lung cancer. However, given its infrequent occurrence, only limited number of preclinical models have been established. Here, we established three LCNEC tumoroids for long-term culture. Whole-exome sequencing revealed that these inherited genetic mutations from their parental tumors; two were (S-LCNEC) and one non-small cell (N-LCNEC). Xenografts in immunodeficient mice mimicked the pathology parent LCNEC, reproduced mixed-tissue types combined component adenocarcinoma. Drug sensitivity tests using enabled evaluation therapeutic agent efficacy. Based on translational research, found CDK4/6 inhibitor might be effective N-LCNEC Aurora A kinase inhibitors suitable S-LCNEC or MYC amplification. These results highlight value tumoroid understanding pathogenesis rare cancers developing treatments. showed high success rate establishment, indicating potential application personalized medicine.

Language: Английский

---

Cryopreservation of human lung tissue for 3D ex vivo analysis

Respiratory Research, Journal Year: 2025, Volume and Issue: 26(1)

Published: May 15, 2025

Language: Английский

---

Lung cancer organoids: models for preclinical research and precision medicine

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Oct. 24, 2023

Lung cancer is a malignancy with high incidence and mortality rates globally, it has 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, drug sensitivity among different lung patients necessitate the development personalized treatment strategies. current precision medicine for cancer, primarily based on pathological genomic testing, fails to meet needs clinically refractory cancer. organoids (LCOs) are derived from tumor cells within tissues generated through three-dimensional tissue culture, enabling them faithfully recapitulate vivo characteristics heterogeneity. establishment series LCOs biobanks offers promising platforms efficient screening identification novel targets anti-tumor discovery. Moreover, provide supplementary decision-making factors enhance thereby addressing limitations associated pathology-guided approaches managing This article presents comprehensive review construction methods potential applications both preclinical research. It highlights significance biomarker exploration, resistance investigation, target identification, screening, as well microfluidic technology-based high-throughput Additionally, discusses future prospects this field.

Language: Английский

---

A systematic review of patient-derived tumor organoids generation from malignant effusions

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 195, P. 104285 - 104285

Published: Feb. 3, 2024

Language: Английский

---